指南与共识支持与姑息治疗头颈与中枢神经肿瘤

药物相关颌骨坏死:MASCC/ISOO/ASCO临床实践指南

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
指南 / 共识 · J Clin Oncol · 2019-07-22

该指南由MASCC/ISOO与ASCO召集多学科专家组制定,系统检索2009至2017年文献并纳入早期综述,共识别132篇出版物(仅10项随机对照试验),经两轮共识投票形成推荐。指南明确MRONJ定义,强调预防性口腔评估、避免择期牙槽外科手术,以及保守治疗为主和多学科协作。

要点

  • MRONJ定义为当前或既往使用BMA或血管生成抑制剂、颌面部暴露骨或可经瘘管探及骨持续超过8周、且无颌部放疗或转移史。
  • 启动BMA前应全面口腔评估、讨论可改变危险因素,治疗期间避免择期牙槽外科手术。
  • MRONJ治疗以保守措施为主,需牙科与肿瘤科持续协作。

核心结论

  • MRONJ的诊断需同时满足BMA或血管生成抑制剂暴露、暴露骨或可探及骨持续超过8周、无颌部放疗或转移史三条标准。
  • 预防性口腔评估和避免择期牙槽外科手术是BMA治疗患者的关键预防措施。
  • MRONJ治疗以保守措施为初始方法,多学科协作对优化患者照护至关重要。

研究设计与样本

  • MASCC/ISOO与ASCO召集多学科专家组,通过系统文献综述和正式共识过程制定指南。
  • 系统综述共识别132篇出版物,其中仅10项为随机对照试验,推荐经两轮共识投票。

主要发现

  • 系统综述识别132篇出版物,仅10项为随机对照试验。
  • MRONJ定义包括当前或既往BMA或血管生成抑制剂治疗、颌面部暴露骨或可经口内或口外瘘管探及的骨持续超过8周、无颌部放疗史或颌部转移性疾病。
  • BMA治疗期间应避免择期牙槽外科手术(涉及牙齿或邻近牙槽骨的手术)。
  • BMA是否应在牙槽外科手术前停用尚不确定。
  • MRONJ分期应由具有MRONJ管理经验的临床医生进行。

关键数值与推荐

  • MRONJ定义第一条:当前或既往使用BMA或血管生成抑制剂。
  • MRONJ定义第二条:颌面部暴露骨或可经口内或口外瘘管探及的骨持续超过8周。
  • MRONJ定义第三条:无颌部放疗史或颌部转移性疾病。
  • 预防措施包括全面牙科评估、讨论可改变危险因素、BMA治疗期间避免择期牙槽外科手术。
  • MRONJ治疗初始方法为保守措施。

临床怎么用

  • 启动BMA前应进行 comprehensive 牙科评估并讨论可改变的危险因素。
  • BMA治疗期间避免择期牙槽外科手术。
  • MRONJ分期应由有经验的临床医生完成,治疗以保守措施为初始 approach。
  • 牙科医生、牙科专科医生与肿瘤科医生应持续协作。

局限性

  • 系统综述识别的132篇出版物中仅10项为随机对照试验。
  • BMA是否应在牙槽外科手术前停用尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer. METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. Guideline development involved a systematic review of the literature and a formal consensus process. PubMed and EMBASE were searched for studies of the prevention and management of MRONJ related to bone-modifying agents (BMAs) for oncologic indications published between January 2009 and December 2017. Results from an earlier systematic review (2003 to 2008) were also included. RESULTS: The systematic review identified 132 publications, only 10 of which were randomized controlled trials. Recommendations underwent two rounds of consensus voting. RECOMMENDATIONS: Currently, MRONJ is defined by (1) current or previous treatment with a BMA or angiogenic inhibitor, (2) exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region and that has persisted for longer than 8 weeks, and (3) no history of radiation therapy to the jaws or metastatic disease to the jaws. In patients who initiate a BMA, preventive care includes comprehensive dental assessments, discussion of modifiable risk factors, and avoidance of elective dentoalveolar surgery (ie, surgery that involves the teeth or contiguous alveolar bone) during BMA treatment. It remains uncertain whether BMAs should be discontinued before dentoalveolar surgery. Staging of MRONJ should be performed by a clinician with experience in the management of MRONJ. Conservative measures comprise the initial approach to MRONJ treatment. Ongoing collaboration among the dentist, dental specialist, and oncologist is essential to optimal patient care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019. PMID: 31329513. doi:10.1200/JCO.19.01186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。